Effect of cardiopulmonary bypass on the pharmacokinetics of propranolol and atenolol

Brazilian Journal of Medical and Biological Research

Volumn 42, Issue 6, 2009, Pages 574-581

  Carmona, Maria J C ^a   Pereira, V A ^a   Malbouisson, L M S ^a   Auler, J O C ^a   Santos, S R C J ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Atenolol; Cardiopulmonary bypass; Coronary artery bypass grafting surgery; Pharmacokinetics; Propranolol

Indexed keywords

ATENOLOL; PROPRANOLOL;

ADULT; ARTERIAL PRESSURE; ARTICLE; CARDIOPULMONARY BYPASS; CARDIOPULMONARY HEMODYNAMICS; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BYPASS GRAFT; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG EFFECT; DRUG HALF LIFE; FEMALE; HEART RATE; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HUMAN; HYPOTHERMIA; ISCHEMIC HEART DISEASE; MALE; OPERATION DURATION; POSTOPERATIVE PERIOD; PREOPERATIVE PERIOD; SURGICAL RISK;

EID: 68149125661     PISSN: 0100879X     EISSN: 1414431X     Source Type: Journal    
DOI: 10.1590/S0100-879X2009000600016     Document Type: Article

References (24)

1. Gersh BJ, Braunwald E, Rutherford JD. Chronic coronary artery disease. In: Braunwald E (Editor), Heart disease: A textbook of cardiovascular medicine. Philadelphia: W.B. Saunders Company; 1997. p 1304-1308.
2. Ryan TJ, Antman EM, Brooks NH, Califf RM, Hillis LD, Hiratzka LF, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction. A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). J Am Coll Cardiol 1999; 34: 890-911.
3. Wallace A, Layug B, Tateo I, Li J, Hollenberg M, Browner W, et al. Prophylactic atenolol reduces postoperative myocardial ischemia. McSPI Research Group. Anesthesiology 1998; 88: 7-17.
4. Mangano DT, Layug EL, Wallace A, Tateo I. Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery. Multicenter Study of Perioperative Ischemia Research Group. N Engl J Med 1996; 335: 1713-1720.
5. Sill JC, Nugent M, Moyer TP, Torres LE, Schaff HV, Tinker JH. Influence of propranolol plasma levels on hemodynamics during coronary artery bypass surgery. Anesthesiology 1984; 60: 455-463.
6. Slogoff S, Keats AS. Does perioperative myocardial ischemia lead to postoperative myocardial infarction? Anesthesiology 1985; 62: 107-114.
7. Boudoulas H, Lewis RP, Snyder GL, Karayannacos P, Vasko JS. Beneficial effect of continuation of propranolol through coronary bypass surgery. Clin Cardiol 1979; 2: 87-91.
8. Mangano DT. Adverse outcomes after surgery in the year 2001 - a continuing odyssey. Anesthesiology 1998; 88: 561-564.
9. Miller RR, Olson HG, Amsterdam EA, Mason DT. Propranolol-withdrawal rebound phenomenon. Exacerbation of coronary events after abrupt cessation of antianginal therapy. N Engl J Med 1975; 293: 416-418.
10. Carmona MJ, Malbouisson LM, Pereira VA, Bertoline MA, Omosako CE, Le Bihan KB, et al. Cardiopulmonary bypass alters the pharmacokinetics of propranolol in patients undergoing cardiac surgery. Braz J Med Biol Res 2005; 38: 713-721.
11. Higgins TL, Estafanous FG, Loop FD, Beck GJ, Blum JM, Paranandi L. Stratification of morbidity and mortality outcome by preoperative risk factors in coronary artery bypass patients. A clinical severity score. JAMA 1992; 267: 2344-2348.
12. Pereira VA, Bertoline MA, Carmona MJC, Auler JOC Jr, Santos SRCJ. High performance liquid chromatography to determine propranolol in plasma. Drug accumulation in postsurgical patients. Braz J Pharmac Sci 2000; 36: 241-247.
13. Winer BJ. Statistical principles in experimental design. New York: McGraw-Hill Book Co.; 1971.
14. Singer JM, Andrade DF. Análise de dados longitudinais. Campinas: VII SINAPE; 1986.
15. Hoffman BB, Lefkowitz RJ. Catecholamines, sympathomimetic drugs, and adrenergic receptor antagonist. In: Hardman JG, Limbird LE (Editors), Goodman & Gilman's - the pharmacological basis of therapeutics. 10th edn. Chicago: McGraw-Hill Companies; 2001. p 215-268.
16. Meier J. Beta-adrenoceptor-blocking agents: pharmacokinetic differences and their clinical implications illustrated on pindolol. Cardiology 1979; 64 (Suppl 1): 1-13.
17. Sager G, Jaeger R, Little C. Binding of prazosin and propranolol at variable alpha 1-acid glycoprotein and albumin concentrations. Br J Clin Pharmacol 1989; 27: 229-234.
18. Rosen DA, Rosen KR. Elimination of drugs and toxins during cardiopulmonary bypass. J Cardiothorac Vasc Anesth 1997; 11: 337-340.
19. Buylaert WA, Herregods LL, Mortier EP, Bogaert MG. Cardiopulmonary bypass and the pharmacokinetics of drugs. An update. Clin Pharmacokinet 1989; 17: 10-26.
20. Mangano DT. Outcome studies in perioperative medicine: The β-blockade trials. In: Tuman KJ (Editor), Outcome measurements in cardiovascular medicine. Chicago: Lippincott Williams & Wilkins; 1999. p 105-124.
21. Ferguson TB Jr, Coombs LP, Peterson ED. Preoperative beta-blocker use and mortality and morbidity following CABG surgery in North America. JAMA 2002; 287: 2221-2227.
22. Boudoulas H, Snyder GL, Lewis RP, Kates RE, Karayannacos PE, Vasko JS. Safety and rationale for continuation of propranolol therapy during coronary bypass operation. Ann Thorac Surg 1978; 26: 222-227.
23. McAllister RG Jr, Bourne DW, Tan TG, Erickson JL, Wachtel CC, Todd EP. Effects of hypothermia on propranolol kinetics. Clin Pharmacol Ther 1979; 25: 1-7.
24. McAllister RG Jr, Tan TG. Effect of hypothermia on drug metabolism. In vitro studies with propranolol and verapamil. Pharmacology 1980; 20: 95-100.